Immunity to liver-stage Plasmodium falciparum in peripheral and tissue-resident immune cells

Recruiting

Conditions: malaria
Plasmodium falciparum
10037072

Registration Number: NL-OMON49766

Lead Sponsor: Radboud Universitair Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Not specified

Target Recruitment: 45

Inclusion Criteria

Patients (M/F) over 18 years of age undergoing medically-indicated partial
liver resection for underlying disease and who have provided written informed
consent.

Exclusion Criteria

Patients who have received immunosuppressive and/or cytostatic agents within
the past 3 months, with the exception of topical or inhaled steroids.

Patients who are known to have infection with humanimmunodeficiency virus
(HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV), or other known
clinically-relevant immunodeficient states.

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>(Refer to Protocol Section 8)<br /><br><br /><br>Study parameters/endpoints<br /><br>Main study endpoints:<br /><br>• Establishment of an in vitro assay to study recognition and killing of P.<br /><br>falciparum-infected hepatocytes by:<br /><br>o cytolytic CD8+ T cells<br /><br>o hepatic and peripheral innate/innate-like lymphocytes</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>(Refer to Protocol Section 8)<br /><br><br /><br>Secondary study endpoints:<br /><br>• Recognition (IFNγ and CD107a expression) and killing (lysis or apoptosis) of<br /><br>P. falciparum-infected hepatocytes by cytolytic CD8+ T cell line<br /><br>• Differences in recognition and killing of P. falciparum-infected hepatocytes<br /><br>between liver-resident and peripheral blood lymphocytes<br /><br>• Identity of the individual lymphocyte (sub-)populations which contribute to<br /><br>recognition and killing of P. falciparum-infected hepatocytes<br /><br></p><br>